News
Vice President Marianne Cunnington Elected to ISPE Board
Analysis Group congratulates Vice President Marianne Cunnington on her election to the Board of the International Society for Pharmacoepidemiology (ISPE) as the representative for industry and service providers in Europe and Africa. ISPE is an international organization that provides a scientific forum for the advancement of pharmacoepidemiology and its role in optimizing drug development and furthering the understanding of drug effects.
Dr. Cunnington has two decades of experience as an industry epidemiologist, generating regulatory grade real-world evidence (RWE) using pharmacoepidemiology methods in support of all stages of drug development. Her election to the Board is an opportunity for Dr. Cunnington to work with her colleagues to promote ISPE’s dedication to robust methods for and innovative approaches to the use of RWE in drug development.
Associated People
Marianne Cunnington
Managing PrincipalDr. Cunnington specializes in regulatory epidemiology, including the design and execution of real-world post-marketing safety and effectiveness studies, as well as real-world studies to support the approval of new products through innovative regulatory pathways. Her research expertise includes design, negotiation, and execution of real-world components of risk management plans for new product submissions with regulators across multiple geographies (US, UK, Europe, Japan, South Korea); post-approval safety studies in the EU; post-marketing requirement and commitment studies in the US; and pregnancy registries. Prior to joining Analysis Group, Dr. Cunnington spent more than 20 years as a pharmaceutical industry epidemiologist focusing on the generation of real-world evidence (RWE) to support the development and life cycle management of vaccines and pharmacological therapies. Dr. Cunnington held several senior epidemiology positions within Novartis and GlaxoSmithKline (GSK). At GSK, she chaired the peer review forum for all pharmaceutical RWE projects, provided epidemiological expertise for the company’s Global Safety Board, and was a managing board member of the Innovative Medicines Initiative’s public-private partnership, building an integrated European real-world data network to monitor medication safety in pregnancy. Dr. Cunnington serves on the board of the International Society for Pharmacoepidemiology as an elected representative of European industry and service providers.